{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:25:48Z","timestamp":1790429148160,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:00:00Z","timestamp":1543017600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de recherche sur le SIDA et les h\u00e9patites virales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Italian Ministry of Education, University and Research"},{"name":"Italian Foundation for Antiviral Studies and Research"},{"name":"AVIRALIA FOUNDATION"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/jac\/dky464","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:16:46Z","timestamp":1542093406000},"page":"614-617","source":"Crossref","is-referenced-by-count":32,"title":["Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients"],"prefix":"10.1093","volume":"74","author":[{"given":"Cathia","family":"Soulie","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"University of Rome \u2018Tor Vergata\u2019, Department of Experimental Medicine and Surgery, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Storto","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Paraskevis","sequence":"additional","affiliation":[{"name":"Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"University of Milan, Paediatric Clinical Research Center \u2018Romeo and Enrica Invernizzi\u2019, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gennari","sequence":"additional","affiliation":[{"name":"University Hospital Polyclinic, Microbiology and Virology Unit, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-0903","authenticated-orcid":false,"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[{"name":"\u2018Careggi\u2019 Hospital, Division of Infectious Diseases, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[{"name":"University of Siena, Department of Medical Biotechnology, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases L. Spallanzani, IRCCS, Antiretroviral Therapy Monitoring Unit, Rome, Italy"},{"name":"Department of Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"University of Rome \u2018Tor Vergata\u2019, Department of Experimental Medicine and Surgery, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"key\n\t\t\t\t2019021507303686800_dky464-B1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","article-title":"Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants","volume":"72","author":"Smith","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B6","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B7","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial","volume-title":"Clin Infect Dis","author":"Orkin","year":"2018"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B8","year":"2016"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B9","year":"2017"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B10","year":"2017"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/1471-2334-14-407","article-title":"Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe","volume":"14","author":"Frentz","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B12","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/jac\/dkv049","article-title":"HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies","volume":"70","author":"Frange","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B13","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/jac\/dkx231","article-title":"Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14","volume":"72","author":"Fabeni","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0b013e328326ca77","article-title":"Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France","volume":"23","author":"Chaix","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.meegid.2017.07.003","article-title":"Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: transmitted drug resistance is due to onward transmissions","volume":"54","author":"Paraskevis","year":"2017","journal-title":"Infect Genet Evol"},{"key":"key\n\t\t\t\t2019021507303686800_dky464-B16","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jac\/dkt238","article-title":"National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011","volume":"68","author":"Descamps","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/3\/614\/27785450\/dky464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:07:18Z","timestamp":1662401238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/3\/614\/5203398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,23]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky464","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,23]]}}}